JP MORGAN 2015: Gilead addresses hepatitis C drug payer deals
This article was originally published in Scrip
Executive Summary
Gilead Sciences president and chief operating officer John Milligan shed a little light on the company's strategy of negotiating US payer reimbursement deals for its newest hepatitis C drug Harvoni (ledipasvir/sofosbuvir), noting a shift from exclusive coverage to shared access to patients.